Strategies for targeting lentiviral vectors

Current Gene Therapy

Volumn 8, Issue 6, 2008, Pages 449-460

  Frecha, Cecilia ^a   Szécsi, Judit ^a,b,c   Cosset, François Loïc ^a,b,c   Verhoeyen, Els ^a,b,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c University Lyon i   (France)

Author keywords

Gene therapy; HIV 1 derived vector; Immune response; MicroRNA; Tissue specific promoters; Transgene

Indexed keywords

CELL SURFACE PROTEIN; DOXYCYCLINE; GANCICLOVIR; LENTIVIRUS VECTOR; MICRORNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THYMIDINE KINASE;

ANTIGEN PRESENTING CELL; DNA MODIFICATION; GENE EXPRESSION; GENE TARGETING; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELL; HOST RANGE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO GENE TRANSFER; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PROMOTER REGION; REGULATORY SEQUENCE; REVIEW; SUICIDE GENE THERAPY; TRANSCRIPTION REGULATION; TRANSGENICS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GLYCOPROTEINS; HIV-1; HUMANS; IMMUNE SYSTEM; LENTIVIRUS; MICRORNAS; PROMOTER REGIONS, GENETIC; RETROVIRIDAE; TRANSGENES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 60649084807     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308786848003     Document Type: Review

References (163)

1. Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID is being confirmed. Lancet 2004; 364: 2155-6.
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-93.
3. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-3.
4. Powell JS, Ragni MV, White GC, 2nd, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102: 2038-45.
5. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-9.
6. Ott MG, Seger R, Stein S, et al. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther 2007; 7: 155-61.
7. Schumbach A, Baum, C. Clinical Application of Lentiviral Vectors, Concept & Practice. Curr Gene Ther 2008; 8: 474-82.
8. Ciuffi A. Mechanisms Governing Lentivirus Integration Site Selection. Curr Gene Ther 2008; 8: 419-29.
9. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992; 11: 3053-8.
10. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 1991; 174: 1477-82.
11. De Palma M, Montini E, Santoni de Sio FR, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005; 105: 2307-15.
12. Zaiss AK, Son S, Chang LJ. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-19.
13. Emery DW, Yannaki E, Tubb J, et al. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002; 100: 2012-9.
14. Starkis C, Philippe S, Mallet J, Serguera C. Non-Integrating Lentiviral Vectors. Curr Gene Ther 2008; 8: ???-???.
15. Annoni A, Battaglia M, Follenzi A, et al. The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. Blood 2007; 110: 1788-96.
16. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-9.
17. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther 2007; 7: 306-15.
18. Heim DA, Hanazono Y, Giri N, et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 2000; 1: 533-44.
19. Kang E, Giri N, Wu T, et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 2001; 12: 1663-72.
20. Beagles KE, Peterson L, Zhang X, Morris J, Kiem HP. Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum Gene Ther 2005; 16: 725-33.
21. Morris JC, Conerly M, Thomasson B, et al. Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood 2004; 103: 492-499.
22. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-27.
23. Negre D, Duisit G, Mangeot PE, et al. Lentiviral vectors derived from simian immunodeficiency virus. Curr Top Microbiol Immunol 2002; 261: 53-74.
24. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-67.
25. Peng KW, Pham L, Ye H, et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 2001; 8: 1456-63.
26. Seganti L, Superti F, Girmenia C, Melucci L, Orsi N. Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica 1986; 9: 259-67.
27. DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2: 218-22.
28. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19: 225-30.
29. Duisit G, Conrath H, Saleun S, et al. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther 2002; 6: 446-54.
30. Lundberg C, Bjorklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: ???-???.
31. Jakobsson J, Lundberg C. Lentiviral vectors for use in the central nervous system. Mol Ther 2006; 13: 484-93.
32. Hanawa H, Kelly PF, Nathwani AC, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242-51.
33. Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206-14.
34. Marandin A, Dubart A, Pflumio F, et al. Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 1998; 9: 1497-511.
35. Movassagh M, Desmyter C, Baillou C, et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 1998; 9: 225-34.
36. Porter CD, Collins MK, Tailor CS, et al. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther 1996; 7: 913-9.
37. Sandrin V, Boson B, Salmon P, et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100: 823-32.
38. Christodoulopoulos I, Cannon PM. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 2001; 75: 4129-38.
39. Lindemann D, Bock M, Schweizer M, Rethwilm A. Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J Virol 1997; 71: 4815-20.
40. Mammano F, Salvatori F, Indraccolo S, et al. Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J Virol 1997; 71: 3341-5.
41. Schnierle BS, Stitz J, Bosch V, et al. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997; 94: 8640-5.
42. Stitz J, Buchholz CJ, Engelstadter M, et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000; 273: 16-20.
43. Takeuchi Y, Simpson G, Vile RG, Weiss RA, Collins MK. Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology 1992; 186: 792-4.
44. Goerner M, Horn PA, Peterson L, et al. Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood 2001; 98: 2065-70.
45. Uckert W, Willimsky G, Pedersen FS, Blankenstein T, Pedersen L. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum Gene Ther 1998; 9: 2619-27.
46. Lavillette D, Boson B, Russell SJ, Cosset FL. Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein. J Virol 2001; 75: 3685-95.
47. Rodrigues P, Heard JM. Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2. J Virol 1999; 73: 3789-99.
48. Battini JL, Danos O, Heard JM. Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor. J Virol 1998; 72: 428-35.
49. Lorimer IA, Lavictoire SJ. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J Immunol Methods 2000; 237: 147-57.
50. Fass D, Davey RA, Hamson CA, et al. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science 1997; 277: 1662-6.
51. Linder M, Linder D, Hahnen J, Schott HH, Stirm S. Localization of the intrachain disulfide bonds of the envelope glycoprotein 71 from Friend murine leukemia virus. Eur J Biochem 1992; 203: 65-73.
52. Linder M, Wenzel V, Linder D, Stirm S. Structural elements in glycoprotein 70 from polytropic Friend mink cell focus-inducing virus and glycoprotein 71 from ecotropic Friend murine leukemia virus, as defined by disulfide-bonding pattern and limited proteolysis. J Virol 1994; 68: 5133-41.
53. Barnett AL, Davey RA, Cunningham JM. Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc Natl Acad Sci U S A 2001; 98: 4113-8.
54. Benedict CA, Tun RY, Rubinstein DB, et al. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 1999; 10: 545-57.
55. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-6.
56. Gollan TJ, Green MR. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J Virol 2002; 76: 3558-63.
57. Valsesia-Wittmann S, Drynda A, Deleage G, et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994; 68: 4609-19.
58. Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology 2000; 269: 7-17.
59. Buchholz CJ, Peng KW, Morling FJ, et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 1998; 16: 951-4.
60. Chadwick MP, Morling FJ, Cosset FL, Russell SJ. Modification of retroviral tropism by display of IGF-I. J Mol Biol 1999; 285: 485-94.
61. Cosset FL, Morling FJ, Takeuchi Y, et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69: 6314-22.
62. Fielding AK, Chapel-Fernandes S, Chadwick MP, et al. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000; 11: 817-26.
63. Fielding AK, Maurice M, Morling FJ, Cosset FL, Russell SJ. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 1998; 91: 1802-9.
64. Kayman SC, Park H, Saxon M, Pinter A. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol 1999; 73: 1802-8.
65. Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 2002; 5: 269-74.
66. Maurice M, Mazur S, Bullough FJ, et al. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood 1999; 94: 401-10.
67. Maurice M, Verhoeyen E, Salmon P, et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 2002; 99: 2342-50.
68. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993; 21: 1081-5.
69. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset FL. Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J 1997; 16: 1214-23.
70. Valsesia-Wittmann S, Morling FJ, Nilson BH, et al. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 1996; 70: 2059-64.
71. Chu TH, Martinez I, Sheay WC, Dornburg R. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther 1994; 1: 292-9.
72. Matano T, Odawara T, Iwamoto A, Yoshikura H. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 1995; 76 (Pt 12): 3165-9.
73. Ager S, Nilson BH, Morling FJ, et al. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther 1996; 7: 2157-64.
74. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 1999; 10: 1533-44.
75. Morizono K, Bristol G, Xie YM, Kung SK, Chen IS. Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001; 75: 8016-20.
76. Patterson SM, Swainsbury R, Routledge EG. Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: separation of attachment and fusion functions on different molecules. Gene Ther 1999; 6: 694-702.
77. Yang L, Bailey L, Baltimore D, Wang P. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A 2006; 103: 11479-84.
78. Pariente N, Mao SH, Morizono K, Chen IS. Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J Gene Med 2008; 10: 242-8.
79. Nilson BH, Morling FJ, Cosset FL, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996; 3: 280-6.
80. Martin F, Neil S, Kupsch J, et al. Retrovirus targeting by tropism restriction to melanoma cells. J Virol 1999; 73: 6923-9.
81. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8: 729-38.
82. Peng KW, Vile R, Cosset FL, Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6: 1552-7.
83. Hartl I, Schneider RM, Sun Y, et al. Library-based selection of retroviruses selectively spreading through matrix metalloproteasepositive cells. Gene Ther 2005; 12: 918-26.
84. Schneider RM, Medvedovska Y, Hartl I, et al. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther 2003; 10: 1370-80.
85. Szecsi J, Drury R, Josserand V, et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006; 14: 735-744.
86. Nguyen TH, Pages JC, Farge D, Briand P, Weber A. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 1998; 9: 2469-79.
87. Sutton RE, Reitsma MJ, Uchida N, Brown PO. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 1999; 73: 3649-60.
88. Kootstra NA, Zwart BM, Schuitemaker H. Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. J Virol 2000; 74: 1712-7.
89. Neil S, Martin F, Ikeda Y, Collins M. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 2001; 75: 5448-56.
90. Dardalhon V, Herpers B, Noraz N, et al. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther 2001; 8: 190-8.
91. Soares MV, Borthwick NJ, Maini MK, et al. IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J Immunol 1998; 161: 5909-17.
92. Webb LM, Foxwell BM, Feldmann M. Putative role for interleukin-7 in the maintenance of the recirculating naive CD4+ T-cell pool. Immunology 1999; 98: 400-5.
93. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, et al. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 2003; 101: 2167-74.
94. Verhoeyen E, Wiznerowicz M, Olivier D, et al. Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 2005; 106: 3386-95.
95. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998; 4: 1253-60.
96. Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood 2002; 100: 862-8.
97. Schiedlmeier B, Klump H, Will E, et al. High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. Blood 2003; 101: 1759-68.
98. Di Domenico C, Di Napoli D, Gonzalez YRE, et al. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 2006; 17: 1112-21.
99. Greenberg KP, Geller SF, Schaffer DV, Flannery JG. Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors. Invest Ophthalmol Vis Sci 2007; 48: 1844-52.
100. Dupre L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/ cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006; 17: 303-13.
101. Khanna AK, Mehra MR. Targeted in vitro and in vivo gene transfer into T lymphocytes: potential of direct inhibition of allo-immune activation. BMC Immunol 2006; 7: 26.
102. Marodon G, Mouly E, Blair EJ, et al. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 2003; 101: 3416-23.
103. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99: 1902-8.
104. Moreau T, Bardin F, Imbert J, Chabannon C, Tonnelle C. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol Ther 2004; 10: 45-56.
105. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105: 829-41.
106. Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 2004; 6: 532-9.
107. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6: 1229-34.
108. Orkin SH, Zon LI. Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat Immunol 2002; 3: 323-8.
109. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008; 132: 631-44.
110. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297: 2256-9.
111. Wang X, Willenbring H, Akkari Y, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 2003; 422: 897-901.
112. Martin F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005; 12: 715-23.
113. Charrier S, Dupre L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007; 14: 415-28.
114. Toscano MG, Frecha C, Benabdellah K, et al. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein. Hum Gene Ther 2008; 19: 179-97.
115. Frecha C, Toscano MG, Costa C, et al. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther 2008; 15: 930-41.
116. Almarza E, Rio P, Meza NW, et al. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. Mol Ther 2007; 15: 1487-94.
117. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.
118. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-9.
119. Prioleau MN, Nony P, Simpson M, Felsenfeld G. An insulator element and condensed chromatin region separate the chicken beta-globin locus from an independently regulated erythroid-specific folate receptor gene. EMBO J 1999; 18: 4035-48.
120. Udvardy A, Maine E, Schedl P. The 87A7 chromomere. Identification of novel chromatin structures flanking the heat shock locus that may define the boundaries of higher order domains. J Mol Biol 1985; 185: 341-58.
121. Rincon-Arano H, Furlan-Magaril M, Recillas-Targa F. Protection against telomeric position effects by the chicken cHS4 beta-globin insulator. Proc Natl Acad Sci USA 2007; 104: 14044-9.
122. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005; 7: 803-17.
123. Recillas-Targa F, Valadez-Graham V, Farrell CM. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. Bioessays 2004; 26: 796-807.
124. Barde I, Zanta-Boussif MA, Paisant S, et al. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol Ther 2006; 13: 382-90.
125. Haack K, Cockrell AS, Ma H, et al. Transactivator and structurally optimized inducible lentiviral vectors. Mol Ther 2004; 10: 585-96.
126. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
127. Rosenzweig M, Connole M, Glickman R, et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951-9.
128. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006; 107: 1828-36.
129. Singer O, Verma IM. Applications on lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 2008; 8: 483-88.
130. Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci U S A 2006; 103: 13759-64.
131. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005; 102: 13212-7.
132. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.
133. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-14.
134. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-91.
135. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007; 109: 2797-805.
136. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25: 1457-67.
137. Yang L, Baltimore D. Long-term in vivo provision of antigenspecific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A 2005; 102: 4518-23.
138. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005; 11: 241-7.
139. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004; 9: 101-11.
140. Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-21.
141. Azzouz M, Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004; 114: 1726-31.
142. Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002; 5: 528-37.
143. Bemelmans AP, Bonnel S, Houhou L, et al. Retinal cell type expression specificity of HIV-1-derived gene transfer vectors upon subretinal injection in the adult rat: influence of pseudotyping and promoter. J Gene Med 2005; 7: 1367-74.
144. Miletic H, Fischer YH, Neumann H, et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther 2004; 15: 1091-100.
145. Stein CS, Martins I, Davidson BL. The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol Ther 2005; 11: 382-9.
146. Kang Y, Stein CS, Heth JA, et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol 2002; 76: 9378-88.
147. Medina MF, Kobinger GP, Rux J, et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther 2003; 8: 777-89.
148. Silvertown JD, Walia JS, Summerlee AJ, Medin JA. Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery. Endocrinology 2006; 147: 3797-808.
149. Hachiya A, Sriwiriyanont P, Patel A, et al. Gene transfer in human skin with different pseudotyped HIV-based vectors. Gene Ther 2007; 14: 648-56.
150. Kang Y, Xie L, Tran DT, et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 2005; 106: 1552-8.
151. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-42.
152. Kowolik CM, Yee JK. Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein. Mol Ther 2002; 5: 762-9.
153. Taher TE, Tulone C, Fatah R, et al. Repopulation of Blymphocytes with restricted gene expression using hematopoietic stem cells engineered with lentiviral vectors. Gene Ther 2008; 15: 998-1006.
154. Laurie KL, Blundell MP, Baxendale HE, et al. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. Gene Ther 2007; 14: 1623-31.
155. Lesniak MS, Kelleher E, Pardoll D, Cui Y. Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells. Neurol Res 2005; 27: 820-6.
156. Endo M, Zoltick PW, Peranteau WH, et al. Efficient in vivo targeting of epidermal stem cells by early gestational intraamniotic injection of lentiviral vector driven by the keratin 5 promoter. Mol Ther 2008; 16: 131-7.
157. Semple-Rowland SL, Eccles KS, Humberstone EJ. Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters. Mol Vis 2007; 13: 2001-11.
158. Yu D, Chen D, Chiu C, et al. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-35.
159. Yu D, Scott C, Jia WW, et al. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Ther 2006; 13: 32-43.
160. Iyer M, Salazar FB, Wu L, Carey M, Gambhir SS. Bioluminescence imaging of systemic tumor targeting using a prostate-specific lentiviral vector. Hum Gene Ther 2006; 17: 125-32.
161. Maatta AM, Korja S, Venhoranta H, et al. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter. Int J Mol Med 2006; 18: 901-8.
162. Barth AS, Kizana E, Smith RR, et al. Lentiviral vectors bearing the cardiac promoter of the Na+-Ca2+ exchanger report cardiogenic differentiation in stem cells. Mol Ther 2008; 16: 957-64.
163. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J Thromb Haemost 2004; 2: 1989-97.